Empowering an AI-Driven Future: Unified Data Architecture Accelerates Oncology Research

Overview

Excelra partnered with a clinical-stage oncology company to unify fragmented datasets and accelerate AI/ML drug discovery through a centralized, FAIR data principles in pharma–aligned ecosystem. By integrating scientific informatics workflows and enabling cancer cohort analytics, the engagement streamlined data access, enhanced predictive modeling capabilities, and reduced research cycle times. This transformation leveraged advanced computational biology services and supported AI-driven insights, with a proven impact highlighted in our Cancer Cohort AI Analysis case study and adherence to fair data principles

Our client

A pioneering clinical-stage oncology company in North America is redefining precision medicine by developing targeted therapies for RAS-addicted cancers. At the forefront of precision oncology and oncology data integration, the organization is committed to transforming patient outcomes by addressing one of the most challenging oncogenic drivers in contemporary cancer biology. Leveraging AI-driven drug discovery and bioinformatics solutions, the company aims to accelerate the development of innovative, targeted therapies.

Client’s challenge

Despite bold ambitions to harness AI/ML drug discovery for oncology research, the client’s data ecosystem was fragmented and this was a major bottleneck. The lack of a unified architecture hindered collaboration, slowed research timelines, and limited the potential of advanced analytics, including cancer cohort analytics.

• Non-FAIR data: Data was not Findable, Accessible, Interoperable, or Reusable—crippling data-driven decision-making and data fairification.
  Inconsistent Standards: Disparate formats, taxonomies, and workflows across departments.
• Siloed systems: No centralized architecture to unify datasets from biology, chemistry, and CROs.
• Delayed collaboration: Disjointed systems slowed internal and external data sharing.
• AI Readiness gap: Infrastructure was not conducive to integrating ML models into research workflows.

Impact:

• Prolonged Design–Make–Test–Analyze (DMTA) cycles.
• Sluggish data exchange with CROs.
• Missed opportunities for cross-domain insights.
• Inefficient use of R&D resources.

Client’s goals

• Empower researchers with data self-service.
• Build AI-ready datasets to accelerate ML/AI use cases.
• Shorten DMTA cycles and fast-track clinical development.

Our approach

Excelra partnered as a digital transformation catalyst—blending domain expertise, scientific informatics, lab informatics, and cutting-edge technology to architect a scalable data foundation.

Key phases:

• Discovery & assessment

  • Conducted deep-dive interviews with biology and chemistry SMEs.

  • Mapped existing data flows with IT and data engineering teams.

• Prioritization & roadmap

  • Identified critical gaps and workflows.

  • Delivered a phased digital transformation roadmap—short, mid, and long-term.

• Technical architecture blueprint

  • Proposed a centralized architecture integrating metadata, RWD, and experimental datasets.

  • Designed a cross-linked framework to unify biological and chemical data.

• AI/ML Enablement

  • Assessed high-impact AI/ML drug discovery use cases.

  • Developed a roadmap for embedding ML models into research pipelines.

• Partner selection & implementation strategy

  • Led RFI/RFP processes for specialized components.

  • Defined scalable workflows for future CRO integration.

For more on scientific informatics services, see Excelra’s scientific application development services.

Key benefits & impact

This transformation unlocked new possibilities in data-driven oncology research:

Data Self-Service

Researchers now access curated datasets instantly—no IT bottlenecks.

40% Efficiency boost

Streamlined collaboration and reduced manual data handling.

AI-Ready ecosystem

A robust framework for deploying ML models in predictive biology and chemistry.

Our solution

Excelra delivered a future-ready data ecosystem aligned with FAIR data principles in pharma and built for AI-driven research.

Core components:

• Data pipeline workflow

  • Secure ingestion from internal and external sources.

  • Validation, harmonization, and modeling for consistency, enabling data fairification.

  • Transformation workflows optimized for analytics and ML readiness.

• Centralized data lake

  • Built on Azure Data Lake for scalable storage and tool integration.

  • GraphQL APIs for seamless access and query optimization.

  • Real-time monitoring via Azure Monitor for data health.

• Scientific data mesh

  • Unified datasets across biology, chemistry, and RWD.

  • Enabled cross-domain sharing with preserved lineage and compliance.

• AI/ML Proof-of-Concept

  • Delivered predictive modeling POC within the discovery pipeline.

  • Established scalable workflows for future AI/ML drug discovery and cancer cohort analytics use cases.

Also see a related case study on Cancer Cohort AI Analysis showcasing AI-driven oncology insights.